BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30236106)

  • 1. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
    Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
    PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
    Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
    Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
    Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
    Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
    Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma.
    Ebata A; Suzuki T; Takagi K; Miki Y; Onodera Y; Nakamura Y; Fujishima F; Ishida K; Watanabe M; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Endocr Relat Cancer; 2012 Aug; 19(4):485-96. PubMed ID: 22569827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
    Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
    Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
    Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
    Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
    Geradts J; Groth J; Wu Y; Jin G
    Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study.
    Rohan TE; Ginsberg M; Wang Y; Couch FJ; Feigelson HS; Greenlee RT; Honda S; Stark A; Chitale D; Wang T; Xue X; Oktay MH; Sparano JA; Loudig O
    BMJ Open; 2021 Oct; 11(10):e053397. PubMed ID: 34702732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.